PMID- 18049022
OWN - NLM
STAT- MEDLINE
DCOM- 20080407
LR  - 20131121
IS  - 0916-9636 (Print)
IS  - 0916-9636 (Linking)
VI  - 30
IP  - 10
DP  - 2007 Oct
TI  - Long-term oral administration of dipyridamole improves both cardiac and physical 
      status in patients with mild to moderate chronic heart failure: a prospective 
      open-randomized study.
PG  - 913-9
AB  - Adenosine is known as an endogenous cardioprotectant. We previously reported that 
      plasma adenosine levels increase in patients with chronic heart failure (CHF), 
      and that a treatment that further elevates plasma adenosine levels may improve 
      the pathophysiology of CHF. Therefore, we performed a prospective, 
      open-randomized clinical trial to determine whether or not exposure to 
      dipyridamole for 1 year improves CHF pathophysiology compared with conventional 
      treatments. The study enrolled 28 patients (mean+/-SEM: 66+/-4 years of age) 
      attending specialized CHF outpatient clinics with New York Heart Association 
      (NYHA) class II or III, no major complications, and stable CHF status during the 
      most recent 6 months under fixed medications. They were randomized into three 
      groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: 
      n=10) in addition to their original medications and were followed up for 1 year. 
      The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, 
      and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, 
      loop diuretics, and beta-adrenoceptor blocker, respectively. Fifteen patients 
      suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from 
      ischemic/valvular/hypertensive heart diseases, respectively. Mean blood pressure 
      was comparable among the groups. While the baseline conditions were comparable, 
      we found that echocardiographic ejection fraction (p<0.01 vs. baseline, p<0.01 
      vs. Control), left ventricular systolic diameter (p<0.05, p<0.05), Specific 
      Activity Scale (SAS) score (p<0.05, p<0.01), maximal oxygen consumption (p<0.05, 
      p<0.05) and plasma B-type natriuretic peptide level (p<0.01, p<0.01) were 
      significantly improved in patients with dipyridamole after 1 year, generally in a 
      dose-dependent manner. Therefore, we suggest that an additional administration of 
      dipyridamole further improves CHF pathophysiology.
FAU - Sanada, Shoji
AU  - Sanada S
AD  - Department of Cardiovascular Medicine, Osaka University Graduate School of 
      Medicine, Suita, Japan.
FAU - Asanuma, Hiroshi
AU  - Asanuma H
FAU - Koretsune, Yukihiro
AU  - Koretsune Y
FAU - Watanabe, Kouki
AU  - Watanabe K
FAU - Nanto, Shinsuke
AU  - Nanto S
FAU - Awata, Nobuhisa
AU  - Awata N
FAU - Hoki, Noritake
AU  - Hoki N
FAU - Fukunami, Masatake
AU  - Fukunami M
FAU - Kitakaze, Masafumi
AU  - Kitakaze M
FAU - Hori, Masatsugu
AU  - Hori M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hypertens Res
JT  - Hypertension research : official journal of the Japanese Society of Hypertension
JID - 9307690
RN  - 0 (Vasodilator Agents)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 64ALC7F90C (Dipyridamole)
SB  - IM
MH  - Aged
MH  - Dipyridamole/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Echocardiography
MH  - Exercise
MH  - Exercise Test
MH  - Female
MH  - Heart Failure/blood/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Prospective Studies
MH  - Vasodilator Agents/*administration & dosage
EDAT- 2007/12/01 09:00
MHDA- 2008/04/09 09:00
CRDT- 2007/12/01 09:00
PHST- 2007/12/01 09:00 [pubmed]
PHST- 2008/04/09 09:00 [medline]
PHST- 2007/12/01 09:00 [entrez]
AID - JST.JSTAGE/hypres/30.913 [pii]
AID - 10.1291/hypres.30.913 [doi]
PST - ppublish
SO  - Hypertens Res. 2007 Oct;30(10):913-9. doi: 10.1291/hypres.30.913.